Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EuroPCR 2021 | CLASP: 2 Year Outcomes of the New Mitral Valve Repair System

The 2-year outcomes of the transcatheter mitral valve repair system PASCAL have shown high survival and low rehospitalization rates, and durable reduction of mitral valve regurgitation. 

CLASP: resultados a 2 años del nuevo dispositivo de reparación Mitral

These results were provided by the CLASP trial, presented during the EuroPCR scientific sessions and simultaneously published in JACC: Cardiovascular Interventions.

The PASCAL system (Edwards) has been authorized for research protocols only in the US.  

At present, patients are being enrolled to the CLASP IID/IIF, set to test the PASCAL against the MitraClip in patients with both functional and degenerative MR. 

If it lives up to its promise, the PASCAL is likely to be authorized by the FDA for use in the clinical arena. 

There are several differences between devices: one is the ability to treat one leaflet after the other, or in tandem. 4th generation MitraClips will offer the same characteristic. 


Read also: Very Short Dual Antiplatelet Therapy after Complex PCI.


The CLASP trial included 124 patients with significant mitral valve regurgitation (≥ 3+) and functional class II to IV who made good candidates for edge-to-edge repair. 

69% of the population had functional mitral valve regurgitation and 60% were in functional class III-IV. Outcomes at 30 days and one year were presented at TCT 2020 and simultaneously published in JACC: Cardiovascular Interventions.

The new outcomes were presented at the EuroPCR; 48 patients that completed the 2 year follow up with 72% survival rate in the functional group and 94% in the degenerative group. 78% of patients presented mitral regurgitation ≤1+, which was accompanied by improved end diastolic volume and functional class. 

Original Title: Durable reduction of mitral regurgitation after 2 years: another ace up the TMVR sleeve.

Reference: Georg Goliasch et al. JACC Cardiovasc Interv. 2021 May 7;S1936-8798(21)00822-0. Online ahead of print. doi: 10.1016/j.jcin.2021.04.047. Presentado simultáneamente en el EuroPCR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

Beyond TAVI: Cardiac Rehabilitation as a Determinant of Clinical Outcomes

Aortic stenosis is an increasingly prevalent condition associated with population aging, with a prevalence of approximately 3.4% in individuals over 75 years of age...

Comparative outcomes between transaxillary approach and thoracotomy-based approaches in TAVI with alternative access

TAVI has become the standard treatment for high-risk aortic stenosis. When transfemoral access is not feasible (approximately 10–15%), alternative approaches are used: transaxillary (subclavian...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...